605 related articles for article (PubMed ID: 35197452)
1. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q; Wu D; Wang X; Xi D; Chen T; Chen G; Wang H; Lu H; Wang M; Zhu L; Hu J; Liu T; Ma K; Han M; Luo X
Signal Transduct Target Ther; 2022 Feb; 7(1):57. PubMed ID: 35197452
[TBL] [Abstract][Full Text] [Related]
2. Immune dysregulation and system pathology in COVID-19.
Jamal M; Bangash HI; Habiba M; Lei Y; Xie T; Sun J; Wei Z; Hong Z; Shao L; Zhang Q
Virulence; 2021 Dec; 12(1):918-936. PubMed ID: 33757410
[TBL] [Abstract][Full Text] [Related]
3. Coagulopathy in COVID-19: Focus on vascular thrombotic events.
Shi W; Lv J; Lin L
J Mol Cell Cardiol; 2020 Sep; 146():32-40. PubMed ID: 32681845
[TBL] [Abstract][Full Text] [Related]
4. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms.
Ahmadian E; Hosseiniyan Khatibi SM; Razi Soofiyani S; Abediazar S; Shoja MM; Ardalan M; Zununi Vahed S
Rev Med Virol; 2021 May; 31(3):e2176. PubMed ID: 33022818
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications.
Tafazoli A; Anil Kumar S; Othman M
Platelets; 2022 Jan; 33(1):48-53. PubMed ID: 34847829
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic events and Covid-19.
Ribes A; Vardon-Bounes F; Mémier V; Poette M; Au-Duong J; Garcia C; Minville V; Sié P; Bura-Rivière A; Voisin S; Payrastre B
Adv Biol Regul; 2020 Aug; 77():100735. PubMed ID: 32773098
[TBL] [Abstract][Full Text] [Related]
7. Potential mechanisms of cerebrovascular diseases in COVID-19 patients.
Lou M; Yuan D; Liao S; Tong L; Li J
J Neurovirol; 2021 Feb; 27(1):35-51. PubMed ID: 33534131
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
9. Peptides: Prospects for Use in the Treatment of COVID-19.
Khavinson V; Linkova N; Dyatlova A; Kuznik B; Umnov R
Molecules; 2020 Sep; 25(19):. PubMed ID: 32987757
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 and Hypercoagulability.
Sholzberg M
Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
[No Abstract] [Full Text] [Related]
11. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
[TBL] [Abstract][Full Text] [Related]
12. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).
Andrew M; Jayaraman G
Carbohydr Res; 2021 Jul; 505():108326. PubMed ID: 34015720
[TBL] [Abstract][Full Text] [Related]
13. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
Haji Aghajani M; Moradi O; Amini H; Azhdari Tehrani H; Pourheidar E; Rabiei MM; Sistanizad M
J Med Virol; 2021 Sep; 93(9):5390-5395. PubMed ID: 33913549
[TBL] [Abstract][Full Text] [Related]
14. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.
Chen Y; Wang J; Liu C; Su L; Zhang D; Fan J; Yang Y; Xiao M; Xie J; Xu Y; Li Y; Zhang S
Mol Med; 2020 Oct; 26(1):97. PubMed ID: 33121429
[TBL] [Abstract][Full Text] [Related]
15. Clotting disorder in severe acute respiratory syndrome coronavirus 2.
Pujhari S; Paul S; Ahluwalia J; Rasgon JL
Rev Med Virol; 2021 May; 31(3):e2177. PubMed ID: 33022790
[TBL] [Abstract][Full Text] [Related]
16. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm.
Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B
Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
[TBL] [Abstract][Full Text] [Related]
18. Lessons from dermatology about inflammatory responses in Covid-19.
Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
[TBL] [Abstract][Full Text] [Related]
19. An Impaired Inflammatory and Innate Immune Response in COVID-19.
Park SH
Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
